Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study.
TNF inhibitor
axial spondyloarthritis
extra-articular manifestations
uveitis
Journal
Therapeutic advances in musculoskeletal disease
ISSN: 1759-720X
Titre abrégé: Ther Adv Musculoskelet Dis
Pays: England
ID NLM: 101517322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
02
2021
accepted:
22
02
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
16
4
2021
Statut:
epublish
Résumé
Acute anterior uveitis (AAU), affecting up to 40% of patients with axial spondyloarthritis (axSpA), risks permanent visual deficits if not adequately treated. We report 2-year results from C-VIEW, the first study to prospectively investigate certolizumab pegol (CZP) on AAU in patients with active axSpA at high risk of recurrent AAU. C-VIEW (NCT03020992) was a 104-week (96 weeks plus 8-week safety follow-up), open-label, multicenter study. Eligible patients had active axSpA, human leukocyte antigen-B27 (HLA-B27) positivity and a history of recurrent AAU (⩾2 AAU flares in total; ⩾1 in the year prior to baseline). Patients received CZP 400 mg at weeks 0, 2 and 4, then 200 mg every 2 weeks to week 96. The primary efficacy endpoint was the AAU flare event rate during 96 weeks' CZP Of 115 enrolled patients, 89 initiated CZP (male: 63%; radiographic/non-radiographic axSpA: 85%/15%; mean disease duration: 9.1 years); 83 completed week 96. There was a significant 82% reduction in AAU flare event rate during CZP CZP treatment significantly reduced AAU flare event rate in patients with axSpA and a history of AAU, indicating CZP is a suitable treatment option for patients at risk of recurrent AAU. NCT03020992, URL: https://clinicaltrials.gov/ct2/show/NCT03020992.
Identifiants
pubmed: 33854572
doi: 10.1177/1759720X211003803
pii: 10.1177_1759720X211003803
pmc: PMC8010825
doi:
Banques de données
ClinicalTrials.gov
['NCT03020992']
Types de publication
Journal Article
Langues
eng
Pagination
1759720X211003803Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: Irene E. van der Horst-Bruinsma: Honoraria/consulting fees/research grants from AbbVie, BMS, MSD, Novartis, Pfizer, UCB Pharma; Rianne E. van Bentum: none; Frank D. Verbraak: Honoraria/consulting fees/research grants from Bayer, Novartis, IDxDR, UCB Pharma; Atul Deodhar: Honoraria/consulting fees/research grants from AbbVie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB Pharma; Thomas Rath: Honoraria/consulting fees from AbbVie, BMS, Chugai, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB Pharma; Bengt Hoepken, Oscar Irvin-Sellers, Lars Bauer: Employees of UCB Pharma; Karen Thomas: Former contractor with UCB Pharma; Martin Rudwaleit: Honoraria/consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, UCB Pharma.
Références
Eye Sci. 2012 Dec;27(4):169-72
pubmed: 23225836
Semin Arthritis Rheum. 2020 Aug;50(4):687-694
pubmed: 32521322
Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509
pubmed: 28498975
Ann Rheum Dis. 2017 Sep;76(9):1515-1521
pubmed: 28254789
Rheumatology (Oxford). 2017 Dec 1;56(12):2060-2067
pubmed: 28340205
J Rheumatol. 2019 Feb;46(2):153-159
pubmed: 30385705
Ann Rheum Dis. 2016 May;75(5):795-810
pubmed: 26888948
Clin Exp Rheumatol. 2019 Jan-Feb;37(1):26-31
pubmed: 30620268
Ther Adv Musculoskelet Dis. 2020 Sep 12;12:1759720X20951733
pubmed: 32963592
Ann Rheum Dis. 2008 Jul;67(7):955-9
pubmed: 17962239
Biomed Res Int. 2018 Oct 14;2018:9460187
pubmed: 30406148
Ophthalmol Retina. 2017 May - Jun;1(3):179-180
pubmed: 31047418
Ann Rheum Dis. 2006 Dec;65(12):1631-4
pubmed: 16901960
Arthritis Res Ther. 2016 Sep 01;18:196
pubmed: 27586785
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
RMD Open. 2020 Apr;6(1):
pubmed: 32371433
Rheumatology (Oxford). 2018 Jun 1;57(6):959-968
pubmed: 29029331
Arthritis Rheum. 2009 Mar;60(3):717-27
pubmed: 19248087
Arthritis Rheumatol. 2019 Jul;71(7):1101-1111
pubmed: 30848558
Clin Exp Optom. 2007 Mar;90(2):70-82
pubmed: 17311570
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S143-5
pubmed: 12463466
Arthritis Rheum. 2005 Aug;52(8):2447-51
pubmed: 16052578
Arthritis Care Res (Hoboken). 2016 Jun;68(6):838-44
pubmed: 26815944
J Rheumatol. 2017 Sep;44(9):1347-1354
pubmed: 28668811
Ann Rheum Dis. 2014 Jan;73(1):39-47
pubmed: 24013647
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299
pubmed: 31436026
Ann Rheum Dis. 2009 May;68(5):696-701
pubmed: 18662932
Arthritis Rheum. 2012 May;64(5):1407-11
pubmed: 22139851
J Rheumatol. 2014 Sep;41(9):1843-8
pubmed: 25086071
Ann Rheum Dis. 2017 Jun;76(6):978-991
pubmed: 28087505
Semin Arthritis Rheum. 2016 Aug;46(1):95-101
pubmed: 27060872